scholarly journals Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy

2016 ◽  
Vol 10 (9-10) ◽  
pp. 300 ◽  
Author(s):  
Mohammadali Mohammadzadeh Rezaei ◽  
Mohammadhadi Mohammadzadeh Rezaei ◽  
Alireza Ghoreifi ◽  
Behzad Feyzzadeh Kerigh
Keyword(s):  
Prostate Cancer ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Safe Alternative ◽  
Metabolic Complications ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Blood Pressures

<p><strong>Introduction:</strong> The presence of metabolic syndrome in men with prostate cancer (PCa) undergoing androgen-deprivation therapy (ADT), especially intermittent type, has not been completely evaluated. The aim of this study is to evaluate metabolic syndrome in men with PCa undergoing intermittent ADT.</p><p><strong>Methods:</strong> In this longitudinal study, we studied the prevalence of metabolic syndrome and its components in 190 patients who were undergoing intermittent ADT. The metabolic syndrome was defined according to the Adult Treatment Panel III criteria. All metabolic parameters, including lipid profile, blood glucose, blood pressures, and waist circumferences of the patients were measured six and 12 months after treatment.</p><p><strong>Results:</strong> Mean age of the patients was 67.5 ± 6.74 years. The incidence of metabolic syndrome after six and 12 months was 6.8% and 14.7%, respectively. Analysis of various components of the metabolic syndrome revealed that patients had significantly higher overall prevalence of hyperglycemia, abdominal obesity, and hypertriglyceridemia in their six- and 12-month followups, but blood pressure has not been changed in the same period except for diastolic blood pressure after six months.</p><p><strong>Conclusions:</strong> Although there was an increased risk of metabolic syndrome in patients receiving intermittent ADT, it was lower than other studies that treated the same patients with continuous ADT. Also it seems that intermittent ADT has less metabolic complications than continuous ADT and could be used as a safe alternative in patients with advanced and metastatic PCa.</p>

Association of metabolic syndrome with reduced survival among men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 56-56 ◽  
Author(s):  
Sarah Maria Rudman ◽  
Kathryn P. Gray ◽  
Julie Kasperzyk ◽  
Michael Pitt ◽  
Edward Giovannucci ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metabolic Syndrome ◽  
Androgen Deprivation Therapy ◽  
Cumulative Incidence ◽  
Androgen Deprivation ◽  
Risk Of Death ◽  
The Metabolic Syndrome ◽  
Obesity And Diabetes ◽  
Increased Risk

56 Background: The metabolic syndrome (MS) is a set of risk factors implicated in both the development of prostate cancer (PC) and as a recognized complication of androgen deprivation therapy (ADT). In our previous study of a Veterans’ Administration (VA) cohort of relapsed PC patients (pts) on ADT, MS was associated with a shorter duration of PC control. Methods: We studied 347 patients (72 from VA and 275 from Health Professionals Follow up Study) treated with ADT for non-metastatic PC. 88% for biochemical relapse post definitive local therapy and 12% treated with primary ADT. MS was assessed by the modified Adult Treatment Panel III criteria prior to the commencement of ADT. Cox models tested for association between MS status and time to overall survival (OS) or time to PC specific survival, stratified by cohorts (VA vs. HPFS). Cumulative incidence of PC specific death (accounting for competing risk of death from other causes and co-morbidities) by MS status was estimated. Results: 96 patients (28%) had MS. 62 patients (18%) died of PC during a median follow-up of 9.5 years. The median OS for patients with and without MS was 7.5 and 10.6 years respectively. A multivariate Cox model adjusted for age at start of ADT, diagnosis, stage, Gleason score and primary treatment showed MS was associated with a significant 53% increased risk of death from any cause (HR(95%CI) 1.53(1.05-2.22); p=0.03). MS patients tended to have increased risk of PC specific death (HR(95%CI) 1.6 (0.9-2.84); p=0.11). Individual MS components hypertension, dyslipidemia, obesity and diabetes were not associated with an increased risk of death from any cause or PC. The cumulative incidence of PC specific death did not differ by MS status. Conclusions In men receiving ADT for androgen dependent PC without metastases, the presence of MS at the commencement of ADT is associated with an increased risk of death compared to those pts without MS. The shorter time to death appears to be at least in part due to shorter time to dying from PC.

The Metabolic Syndrome and its Components in Patients with Prostate Cancer on Androgen Deprivation Therapy

2015 ◽  
Vol 193 (6) ◽  
pp. 1963-1969 ◽  
Author(s):  
Juan Morote ◽  
Antonio Gómez-Caamaño ◽  
José L. Alvarez-Ossorio ◽  
Daniel Pesqueira ◽  
Angel Tabernero ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metabolic Syndrome ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
The Metabolic Syndrome

scholarly journals Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis

2008 ◽  
Vol 93 (6) ◽  
pp. 2042-2049 ◽  
Author(s):  
Sadeka Shahani ◽  
Milena Braga-Basaria ◽  
Shehzad Basaria
Keyword(s):  
Prostate Cancer ◽  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Androgen Deprivation Therapy ◽  
Cardiovascular Mortality ◽  
Prospective Studies ◽  
Androgen Deprivation ◽  
Negative Consequences ◽  
Metabolic Complications

Abstract Context: Prostate cancer (PCa) is the most common cancer in men. Androgen-deprivation therapy (ADT) is generally employed in the treatment of locally advanced and metastatic PCa. Although its use as an adjuvant therapy has resulted in improved survival in some patients, ADT has negative consequences. Complications like osteoporosis, sexual dysfunction, gynecomastia, and adverse body composition are well known. Recently, metabolic complications like insulin resistance, diabetes, dyslipidemia, and metabolic syndrome have emerged, which may be responsible for the increased cardiovascular mortality in this population. Evidence Acquisition: A MEDLINE search was conducted for articles published over the last 20 yr based on the key words androgen deprivation therapy AND insulin resistance, hyperglycemia, diabetes, dyslipidemia, metabolic syndrome, and cardiovascular disease. Relevant studies in non-PCa populations evaluating the association between testosterone and metabolism were also reviewed and briefly mentioned where relevant. Evidence Synthesis: Prospective studies evaluating early (3–6 months) metabolic changes of ADT show development of hyperinsulinemia; however, glucose levels remain normal. Cross-sectional studies of men undergoing long-term (≥12 months) ADT reveal higher prevalence of diabetes and metabolic syndrome compared with controls. Furthermore, men undergoing ADT also experience higher cardiovascular mortality. Conclusion: Long-term prospective studies of ADT are needed to determine the timing of onset of these metabolic complications and to investigate the mechanism behind them. In the meantime, we recommend baseline and serial screening for fasting glucose, lipids, and other cardiovascular risk factors in men receiving ADT. Glucose tolerance tests and cardiac evaluation may be required in selected cases.

598: Increased Risk of Newly Diagnosed Comorbidities in Prostate Cancer Patients Treated with Androgen Deprivation Therapy

2007 ◽  
Vol 177 (4S) ◽  
pp. 200-200 ◽  
Author(s):  
Andrea Gallina ◽  
Pierre I. Karakiewicz ◽  
Jochen Walz ◽  
Claudio Jeldres ◽  
Quoc-Dien Trinh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Newly Diagnosed ◽  
Increased Risk

scholarly journals Inflammation, obesity and comorbidities: the role of diet

2007 ◽  
Vol 10 (10A) ◽  
pp. 1164-1172 ◽  
Author(s):  
Mónica Bulló ◽  
Patricia Casas-Agustench ◽  
Pilar Amigó-Correig ◽  
Javier Aranceta ◽  
Jordi Salas-Salvadó
Keyword(s):  
Metabolic Syndrome ◽  
Virgin Olive Oil ◽  
Plasminogen Activator Inhibitor ◽  
Overweight And Obesity ◽  
Factor Vii ◽  
Processed Meat ◽  
Obese People ◽  
Metabolic Complications ◽  
The Metabolic Syndrome ◽  
Increased Risk

AbstractThe adipocyte metabolism has been shown to change during the fat enlargement process associated to obesity. Several procoagulant proteins such as plasminogen activator inhibitor type 1, tissue factor or factor VII and also inducible nitric oxide synthase show higher expression in adipose tissue of obese people in comparison to lean. This overexpression could explain at least a part of the atherogenic and cardiovascular risk associated with obesity.In addition to cytokine secretion, many other features have been observed to be common to adipocyte and monocyte/macrophage lines: for example, phagocytic and microbicidal activities, and possibly a cellular plasticity of adipose precursors.Overweight and obesity are associated with an increased risk of such metabolic abnormalities as dyslipidemia, hypertension or type 2 diabetes mellitus and cardiovascular diseases, common features of the metabolic syndrome. Initially, insulin resistance or hyperinsulinemia was suggested as the origin of these abnormalities. More recent studies indicate that adipokynes have an important role in obesity-associated metabolic complications, and suggest that chronically elevated local or systemic concentrations of adipokynes contribute to the development of complications associated with obesity and metabolic syndrome.Considering all the evidence relating to diet and inflammation, the best diet for protecting against the metabolic derangements associated with obesity and metabolic syndrome would be high in fibre-rich cereals, fruit, vegetables, fish, virgin olive oil and nuts; moderate in wine; and low in meat, processed meat foods and trans-fatty acids.

Sign in / Sign up

Export Citation Format

Share Document